ClinicalTrials.gg
CompletedNCT03292146Updated Nov 4, 2025Results posted

Effects of Denosumab on Bone Mineral Density in Women With Anorexia Nervosa: A Pilot Study

A Phase 3 interventional study of Denosumab 60 MG [Prolia] and Placebo Injection in Bone Density, Bone Loss and Anorexia Nervosa, sponsored by Massachusetts General Hospital. Completed at 1 site in United States. Open to female participants aged 20 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-11-04.

Sponsored by Massachusetts General Hospital · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
20 Years to 60 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 25 studies testing denosumab in Bone Diseases, Metabolic — 1 open to participants now, 1 under way, none of them phase 3. Denosumab · Bone Diseases, Metabolic.

Enrollment
22nd of 25
30 · median 100
Started
2017
the only one that year
Phase 3
13 of 25
none open now
Registered
18th of 25
by date
Lead sponsor
2 of 25
Massachusetts General Hospital

Among the 25 studies testing denosumab in Bone Diseases, Metabolic, this one is the 22nd largest by enrollment, is the only one that started in 2017, is one of 13 in phase 3, and was the 18th registered.

Bone Diseases, Metabolic

662 studies on the registry are indexed under Bone Diseases, Metabolic; 94 are open to participants now.

Browse Bone Diseases, Metabolic studies →

Open to participants now

1 of the 25 studies testing denosumab in Bone Diseases, Metabolic is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About denosumab

Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 64 Bone Diseases, Metabolic studies recruiting now, 28 (44%) set no upper age limit and 28 (44%) stop at 75 or younger; 12 take children under 18; 22 take healthy volunteers.

This study: 20 Years to 60 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing denosumab in Bone Diseases, Metabolic, or all of them as a file.
02

Study summary

This protocol is a randomized, double-blind, placebo-controlled clinical trial which aims to investigate the effect of denosumab on BMD in women with anorexia nervosa. The investigators hypothesize that 12 months of denosumab administration will result in an increase in bone mineral density, decrease in markers of bone resorption and improvement in bone microarchitecture in osteopenic women with anorexia nervosa compared with placebo.

An optional extension study will offer subjects 12-month administration of open-label alendronate (an oral bisphosphonate) after the initial 12 month administration of denosumab or placebo. We hypothesize that 12 months of denosumab followed by 12 months of open-label alendronate will result in a greater increase in BMD compared to 12 months of placebo followed by 12 months of open-label alendronate. Within the group of women who receive sequential therapy with 12 months of denosumab followed by 12 months of alendronate, we hypothesize that BMD will be maintained between 12 and 24 months while on alendronate.

03

Conditions studied

  • Bone Density
  • Bone Loss
  • Anorexia Nervosa
  • Eating Disorder
  • Atypical Anorexia Nervosa
04

Who can participate

Ages eligible
20 Years to 60 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Inclusion/Exclusion Criteria:

Inclusion Criteria:

  • Female
  • Age 20-60 years, skeletally mature with closed epiphyses
  • Anorexia nervosa or atypical anorexia nervosa defined by diagnostic criteria
  • BMD T-score \< -1.0
  • Normal serum 25-OH vitamin D (>30 ng/mL) and calcium levels
  • For women of reproductive age, agree to use an effective method. Highly effective methods of birth control include:

    • Combined (estrogen and progestogen) hormonal methods (pills, vaginal ring, or skin patch)
    • Intrauterine device (IUD)
    • Intraduterine hormonal-releasing system (IUS)
    • Surgery to tie both fallopian tubes (bilateral tubal ligation/occlusion)
    • Your male partner has had a vasectomy and testing shows there is no sperm in the semen
  • Dental check up within the past year

Exclusion Criteria:

  • Any disease known to affect bone, including untreated thyroid dysfunction, Cushing's or renal failure
  • Subjects with a known esophageal disease cannot participate in the alendronate extension study
  • Any medication known to affect bone metabolism within 3 months of the study, excluding oral contraceptives or other forms of estrogen administration. Bisphosphonates must have been discontinued for at least one year before participation
  • Immunodeficiency or taking therapy
  • Serum potassium \<3.0 meq/L
  • Serum >3 times
  • of less than 30 ml/min
  • Hypocalcemia
  • Diabetes mellitus
  • Active substance abuse, including alcohol
  • History of
  • Paget disease of bone
  • Osteomalacia
  • Osteonecrosis of the jaw (ONJ) or risk factor for ONJ, such as invasive dental procedures (eg, tooth extraction, dental implants, oral surgery in the past 6 months), poor oral hygiene, periodontal and/or pre-existing dental disease, and current use of .
  • Planned invasive dental procedure over the next 24 months.
  • Known senstivity to any of the products or components to be administered during dosing or known sensitivity to mammalian cell derived drug products
  • Sensitivity to calcium or vitamin D supplements
  • Pregnant, planning to become pregnant with 7 months after the end of treatment and/or breastfeeding
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Active Denosumab 60mg Injection

    Denosumab 60mg injection at baseline study visit and 6 month study visit. Alendronate 70mg PO weekly starting at Month 12 through 24 months.

    Drug: Denosumab 60 MG [Prolia] · Drug: Alendronate 70Mg Tab

  • Placebo comparator
    Placebo

    Placebo injection at baseline study visit and 6 month study visit. Alendronate 70mg PO weekly starting at Month 12 through 24 months.

    Drug: Placebo Injection · Drug: Alendronate 70Mg Tab

Interventions

  • Denosumab 60mg injection at baseline and 6 months

  • DrugPlacebo Injection

    Placebo Injection at baseline and 6 months

  • Alendronate 70mg PO weekly starting at Month 12 through 24 months.

06

What researchers measure

Primary outcomes

  1. Postero-anterior (PA) Lumbar Spine Bone Mineral Density by Dual-energy X-ray Absorptiometry (DXA)

    Postero-anterior (PA) lumbar spine bone mineral density was assessed by dual-energy x-ray absorptiometry (DXA). The DXA scanner used was a Hologic Horizon A (Hologic, Inc., Waltham, MA).

    Time frame: 12 months (Period 1)

Secondary outcomes

  1. Percent Change Postero-anterior (PA) Lumbar Spine Bone Mineral Density by DXA

    Time frame: Baseline to 24 months

  2. Percent Change Postero-anterior (PA) Lumbar Spine Bone Mineral Density by DXA

    Time frame: 12 months to 24 months (Period 2)

07

Results

Posted Oct 12, 2022

Participant flow

Women, age 20-60 years, with anorexia nervosa or atypical anorexia nervosa and BMD T-score \< -1.0

Baseline to 12 months
Participant flow — Baseline to 12 months
MilestoneDenosumab (0-12 months) followed by alendronate (12-24 months)Placebo (0-12 months) followed by alendronate (12-24 months)
Started2010
Completed189
Not completed21
Withdrew: Relocation10
Withdrew: Seeking higher level of care for eating disorder10
Withdrew: Seeking treatment for chronic fatigue syndrome01
12 months to 24 months
Participant flow — 12 months to 24 months
MilestoneDenosumab (0-12 months) followed by alendronate (12-24 months)Placebo (0-12 months) followed by alendronate (12-24 months)
Started189
Completed156
Not completed33
Withdrew: Planning pregnancy22
Withdrew: Personal reasons10
Withdrew: Lost to follow-up01

Outcome measures

PrimaryPostero-anterior (PA) Lumbar Spine Bone Mineral Density by Dual-energy X-ray Absorptiometry (DXA)

Postero-anterior (PA) lumbar spine bone mineral density was assessed by dual-energy x-ray absorptiometry (DXA). The DXA scanner used was a Hologic Horizon A (Hologic, Inc., Waltham, MA).

Time frame:
12 months (Period 1)
Reported as:
Least squares mean · g/cm^2
Postero-anterior (PA) Lumbar Spine Bone Mineral Density by Dual-energy X-ray Absorptiometry (DXA)
g/cm^2Denosumab (0-12 months) followed by alendronate (12-24 months)Placebo (0-12 months) followed by alendronate (12-24 months)
Postero-anterior (PA) Lumbar Spine Bone Mineral Density by Dual-energy X-ray Absorptiometry (DXA)0.90 ± 0.030.87 ± 0.04
Statistical analysis
  • Denosumab (0-12 months) followed by alendronate (12-24 months) vs Placebo (0-12 months) followed by alendronate (12-24 months) · Mixed Models Analysis · p = 0.009
SecondaryPercent Change Postero-anterior (PA) Lumbar Spine Bone Mineral Density by DXA
Time frame:
Baseline to 24 months
Reported as:
Mean · % change
Percent Change Postero-anterior (PA) Lumbar Spine Bone Mineral Density by DXA
% changeDenosumab (0-12 months) followed by alendronate (12-24 months)Placebo (0-12 months) followed by alendronate (12-24 months)
Percent Change Postero-anterior (PA) Lumbar Spine Bone Mineral Density by DXA3.9 ± 4.35.8 ± 5.3
Statistical analysis
  • Denosumab (0-12 months) followed by alendronate (12-24 months) vs Placebo (0-12 months) followed by alendronate (12-24 months) · t-test, 2 sided · p = 0.41
SecondaryPercent Change Postero-anterior (PA) Lumbar Spine Bone Mineral Density by DXA
Time frame:
12 months to 24 months (Period 2)
Reported as:
Mean · % change
Percent Change Postero-anterior (PA) Lumbar Spine Bone Mineral Density by DXA
% changeDenosumab (0-12 months) followed by alendronate (12-24 months)Placebo (0-12 months) followed by alendronate (12-24 months)
Percent Change Postero-anterior (PA) Lumbar Spine Bone Mineral Density by DXA-2.0 ± 3.74.6 ± 3.2
Statistical analysis
  • Denosumab (0-12 months) followed by alendronate (12-24 months) · Matched pairs · p = 0.06
  • Placebo (0-12 months) followed by alendronate (12-24 months) · Matched pairs · p = 0.01

Adverse events

Collected over Baseline to 24 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Denosumab (0-12 months) followed by alendronate (12-24 months)0/20 (0%)0/20 (0%)6/20 (30%)
Placebo (0-12 months) followed by alendronate (12-24 months)0/10 (0%)0/10 (0%)3/10 (30%)
Most frequent other events
Most frequent other events
EventDenosumab (0-12 months) followed by alendronate (12-24 months)Placebo (0-12 months) followed by alendronate (12-24 months)
constipationGastrointestinal disorders3/200/10
COVID-19Infections and infestations1/201/10
bone fractureInjury, poisoning and procedural complications1/201/10
Gallbladder biliary dyskinesiaGastrointestinal disorders0/201/10
nausea/stomach pain/bloatingGastrointestinal disorders1/200/10
KeratitisInfections and infestations1/200/10
C. difficileInfections and infestations1/200/10
Disc degeneration and herniationInjury, poisoning and procedural complications1/200/10

Baseline characteristics

Women, age 20-60 years, with anorexia nervosa or atypical anorexia nervosa and BMD T-score \< -1.0

Age, Categorical
Age, Categorical(Participants)Denosumab (0-12 months) followed by alendronate (12-24 months)Placebo (0-12 months) followed by alendronate (12-24 months)Total
<=18 years000
Between 18 and 65 years201030
>=65 years000
Age, Continuous
Age, Continuous(years)Denosumab (0-12 months) followed by alendronate (12-24 months)Placebo (0-12 months) followed by alendronate (12-24 months)Total
Mean29.2 ± 8.029.4 ± 6.829.3 ± 7.5
Sex: Female, Male
Sex: Female, Male(Participants)Denosumab (0-12 months) followed by alendronate (12-24 months)Placebo (0-12 months) followed by alendronate (12-24 months)Total
Female201030
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Denosumab (0-12 months) followed by alendronate (12-24 months)Placebo (0-12 months) followed by alendronate (12-24 months)Total
Hispanic or Latino000
Not Hispanic or Latino201030
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Denosumab (0-12 months) followed by alendronate (12-24 months)Placebo (0-12 months) followed by alendronate (12-24 months)Total
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American000
White191029
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Denosumab (0-12 months) followed by alendronate (12-24 months)Placebo (0-12 months) followed by alendronate (12-24 months)Total
United States201030
Body mass index (BMI)
Body mass index (BMI)(kg / m^2)Denosumab (0-12 months) followed by alendronate (12-24 months)Placebo (0-12 months) followed by alendronate (12-24 months)Total
Mean19.0 ± 1.718.0 ± 2.018.7 ± 1.9
Postero-anterior (PA) lumbar spine areal bone mineral density (aBMD) Z-score
Postero-anterior (PA) lumbar spine areal bone mineral density (aBMD) Z-score(Z-score)Denosumab (0-12 months) followed by alendronate (12-24 months)Placebo (0-12 months) followed by alendronate (12-24 months)Total
Mean-1.6 ± 0.9-1.7 ± 1.4-1.6 ± 1.1

1 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2017 to primary completion in Jul 2021, 44 months.

Results were first posted in Oct 2022, 1 year 2 months after primary completion.

Of 26 phase 3 interventional studies under Bone Diseases, Metabolic, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 57. This study's 44 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2017
First posted
Sep 25, 2017
StartActual
Oct 25, 2017
Primary completionActual
Jul 22, 2021
CompletionActual
Jul 22, 2021
Results first posted
Oct 12, 2022
Last update
Nov 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03292146
Collaborators
Amgen
Responsible party
Karen Klahr Miller, MD (Professor of Medicine, Massachusetts General Hospital) — Principal investigator
First posted
Sep 25, 2017
Start date
Oct 25, 2017
Primary completion
Jul 22, 2021
Completion
Jul 22, 2021
Results posted
Oct 12, 2022
Last update
Nov 4, 2025

Study contacts

Karen K Miller, MD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion